Age Considerations for Findings on Venetoclax Combined With CLIA for AML, High-Risk MDS
December 29th 2022Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, explains the implications of the longer-term follow-up of venetoclax in combination with the chemotherapy regimen cladribine, high-dose cytarabine, idarubicin (CLIA) and how age is a factor when considering chemotherapy options.
Susan Sabo-Wagner Cites Challenges With Home Care for Patients With Cancer
December 26th 2022Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy for Oncology Consultants of Houston, Texas, discussed how housing conditions can impede positive outcomes for patients with cancer who are receiving cancer care support at home.
Top 5 Most-Read MDD Articles of 2022
December 24th 2022The top 5 most-read articles on major depressive disorder (MDD) in 2022 discussed US treatment updates, drug assistance in talk therapy, further exploration of transcranial magnetic stimulation’s capabilities, and screening improvements and outcomes.
Biosimilars Are a "Wonderful" Option for Patients With Cancer, Says Susan Sabo-Wagner
December 23rd 2022Biosimilars are a wonderful option for patients, but the growing number available can be challenging to manage when different payers prefer different agents, said Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy for Oncology Consultants of Houston, Texas.
Top 5 Most-Read Rare Disease Articles of 2022
December 23rd 2022The most-read rare disease articles of the year included the topics of new pediatric central nervous system tumor guidelines, graft versus host disease, the contribution of gene variants to pediatric neuropsychiatric conditions, and hope for patients with blast-phase chronic myeloid leukemia.
Different Types of Support Are Essential for Home Cancer Care, Says Susan Sabo-Wagner
December 20th 2022Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy for Oncology Consultants of Houston, Texas, talked about the importance of having adequate support not only from clinical staff, but also emotional and moral support at home.
Dr Kyle Lamb Discusses Transitional Care, Super-Utilization in Value-Based Medicine
December 19th 2022Kyle Lamb, MD, associate medical director of population health at Vancouver Clinic, discusses how super-utilization trends have changed since the start of COVID-19, the necessity of transitional care in implementing value-based medicine, and how technology can decrease super-utilization.
Dr Patrick Reville Covers Study Results on Venetoclax Combined With CLIA
December 16th 2022Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, discusses findings on an updated treatment regimen for newly-diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Telemedicine Care Quality, Social Vulnerability Index Barriers Measured for Patients With Epilepsy
December 12th 2022Abstracts from the American Epilepsy Society annual meeting show that telemedicine is capable of meeting the needs of patients with epilepsy, and that the patient portal accessibility for patients experiencing high social vulnerability index needs further research.
Dr Steven Pipe: What to Watch for in the Hemophilia Therapy Pipeline
December 10th 2022The field of hemophilia therapy is advancing, with hemostatic rebalancing agents and gene therapy expected over the next year, said Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory.
Two Pediatric Tertiary Care Centers Evaluate Efficacy of CBD on Refractory, Intractable Epilepsy
December 9th 2022Abstracts from the American Epilepsy Society (AES) display potential benefits of cannabidiol (CBD) on pediatric patients with epilepsy in tertiary care centers and highlight areas where further research is needed.
Safety and Efficacy of New Hemophilia Treatments Are Most Important, Patients Report
December 7th 2022Safety and efficacy were the most important factors for patients with hemophilia learning about gene therapies, although more research is needed to see how collaboration between providers and patients contributes to the best outcomes.
Dr Neil Iyengar Previews SABCS Presentation on Metabolic Dysregulation in Breast Cancer
December 5th 2022Neil Iyengar, MD, from Memorial Sloan Kettering Cancer Center, is expecting updates on therapies to fight human epidermal growth factor 2 (HER2)–positive breast cancer and novel antibody drug conjugates at the upcoming San Antonio Breast Cancer Symposium (SABCS).
Dr Steven Pipe on Current Trends in Hemophilia Incidence
December 2nd 2022About 1 in 5000 males are born with hemophilia, according to Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program.